NASDAQ: KNSAKiniksa Pharmaceuticals International PLC Stock
$65.38+0.62 (+0.96%)
Updated Jul 9, 2026
KNSA Price
$65.38
Fair Value Price
N/A
Market Cap
$5.03B
52 Week Low
$26.27
52 Week High
$67.53
P/E
66.71x
P/B
8.3x
P/S
4.89x
PEG
1.81x
Dividend Yield
N/A
Revenue
$754.05M
Earnings
$73.06M
Gross Margin
89.3%
Operating Margin
14.06%
Profit Margin
9.7%
Debt to Equity
0.36
Operating Cash Flow
$166M
Beta
0.8
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KNSA Overview
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KNSA's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +28.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KNSA
Ranked#10 of 462
Ranked#10 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $246.91 | A | |
| $11.46 | A | |
| $16.59 | A |
Be the first to know about important KNSA news, forecast changes, insider trades & much more!
KNSA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KNSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KNSA ($65.38) is trading above its intrinsic value of $16.98, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
KNSA is poor value based on its earnings relative to its share price (66.71x), compared to the US market average (9.97x)
P/E vs Market Valuation
KNSA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more KNSA due diligence checks available for Premium users.
Valuation
KNSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
66.71x
Industry
16.82x
Market
9.97x
KNSA is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
KNSA is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
KNSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.3x
Industry
5.64x
KNSA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KNSA price to earnings growth (PEG)
For valuing profitable companies with growth potential
KNSA is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
KNSA's financial health
Profit margin
Revenue
$214.3M
Net Income
$22.6M
Profit Margin
10.5%
KNSA's Earnings (EBIT) of $105.98M... subscribe to Premium to read more.
Interest Coverage Financials
KNSA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$825.3M
Liabilities
$219.6M
Debt to equity
0.36
KNSA's short-term assets ($594.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KNSA's short-term assets ($594.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KNSA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KNSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$50.2M
Investing
-$31.9M
Financing
$6.1M
KNSA's operating cash flow ($165.86M)... subscribe to Premium to read more.
Debt Coverage Financials
KNSA vs Biotech Stocks
Kiniksa Pharmaceuticals International Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.